Skip to Main Content

In a victory for AbbVie (ABBV), the U.S. International Trade Commission decided that imports of a rival to its Botox wrinkle treatment must be halted for 21 months.

The ruling came in response to a complaint filed last year by Allergan, which AbbVie has since acquired, alleging that a pair of rival companies — Evolus (ELOS) and Daewoong Pharmaceuticals — stole trade secrets that were used to develop a new wrinkle-smoothing product called Jeuveau.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!